DF6002

DRUG2 trials

Sponsors

Dragonfly Therapeutics Inc., Dragonfly Therapeutics

Conditions

Advanced Solid TumorsSolid Tumors

Phase 1

A Study of DF6002 Alone and in Combination With Nivolumab

CompletedNCT04423029

Dragonfly TherapeuticsSolid Tumors

Start: 2020-07-13End: 2025-11-26Updated: 2026-03-18

A Phase 1/2, First-In-Human, Multi-Part, Open Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of DF6002 as a Monotherapy and in Combination with Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion in Selected Indications

CompletedCTIS2023-510511-19-00

Dragonfly Therapeutics Inc.Advanced Solid Tumors

Start: 2021-11-08End: 2025-11-19Target: 95Updated: 2025-04-25

Related Papers

Abstract 1714: Preclinical characterization of DF6002/BMS-986415, a novel differentiated IL-12 Fc-fusion protein with robust antitumor activity as monotherapy or in combination with anti-PD-1

Cancer Research2021-07-015 citations